BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27262102)

  • 21. Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework.
    Bhatia R; Alcaniz Boada E; Bonde JH; Quint WGV; Xu L; Ejegod DM; Cuschieri K; Arbyn M
    J Clin Pathol; 2023 Mar; 76(3):172-176. PubMed ID: 34782423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium.
    Bonde J; Ejegod DM; Cuschieri K; Dillner J; Heideman DAM; Quint W; Pavon Ribas MA; Padalko E; Christiansen IK; Xu L; Arbyn M
    J Clin Virol; 2018 Nov; 108():64-71. PubMed ID: 30253376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
    Akbari A; Vanden Broeck D; Benoy I; Padalko E; Bogers J; Arbyn M
    Virol J; 2018 Oct; 15(1):166. PubMed ID: 30373616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay.
    Benoy I; Xu L; Vanden Broeck D; Poljak M; Oštrbenk Valenčak A; Arbyn M; Bogers J
    J Clin Virol; 2019 Nov; 120():57-62. PubMed ID: 31569008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PCR-RFLP assay as an option for primary HPV test.
    Golfetto L; Alves EV; Martins TR; Sincero TCM; Castro JBS; Dannebrock C; Oliveira JG; Levi JE; Onofre ASC; Bazzo ML
    Braz J Med Biol Res; 2018 Mar; 51(5):e7098. PubMed ID: 29590262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of HarmoniaHPV test for detection of clinically significant Human Papillomavirus infection using the VALGENT framework.
    Bhatia R; Boada EA; Bonde J; Quint W; Christiansen IK; Xu L; Ejegod DM; Moncur S; Cuschieri K; Arbyn M
    J Virol Methods; 2021 Aug; 294():114161. PubMed ID: 33895238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China.
    Xu H; Lin A; Shao X; Shi W; Zhang Y; Yan W
    Oncotarget; 2016 Dec; 7(50):83775-83783. PubMed ID: 27626178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of EUROArray HPV test using the VALGENT framework.
    Viti J; Poljak M; Oštrbenk A; Bhatia R; Alcañiz Boada E; Cornall AM; Cuschieri K; Garland S; Xu L; Arbyn M
    J Clin Virol; 2018 Nov; 108():38-42. PubMed ID: 30223253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of a novel microplate colorimetric hybridization genotyping assay for human papillomavirus.
    Barcellos RB; Almeida SE; Sperhacke RD; Verza M; Rosso F; Medeiros RM; Perizzolo PF; Cortez-Herrera E; Rossetti ML
    J Virol Methods; 2011 Oct; 177(1):38-43. PubMed ID: 21807028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.
    Dhillon SK; Oštrbenk Valenčak A; Xu L; Poljak M; Arbyn M
    J Clin Microbiol; 2021 May; 59(6):. PubMed ID: 33731413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concordance of Anyplex™ II HPV HR assays with reference HPV assays in cervical cancer screening: Systematic review.
    Biazin H
    J Virol Methods; 2022 Mar; 301():114435. PubMed ID: 34919974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
    Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
    Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.
    Dalstein V; Merlin S; Bali C; Saunier M; Dachez R; Ronsin C
    J Virol Methods; 2009 Mar; 156(1-2):77-83. PubMed ID: 19041893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
    Poljak M; Oštrbenk A
    Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High performance of combined HPV testing and genotyping for HPV16/18/52/58 in triaging women with minor cervical cytological abnormalities in northern Thailand.
    Khunamornpong S; Settakorn J; Sukpan K; Srisomboon J; Intaraphet S; Siriaunkgul S
    J Med Virol; 2016 Jan; 88(1):135-43. PubMed ID: 26129775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework.
    Xu L; Oštrbenk Valenčak A; Poljak M; Arbyn M
    J Clin Microbiol; 2020 May; 58(6):. PubMed ID: 32245832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human papillomavirus typing by single tube multiplex amplification in real time (SMART): the PapillomaFinder® SMART 20 assay.
    Ossel J; Litjens RJ; Reijans M; Brink AA; Ummelen M; Ramaekers FC; Hopman AH; Simons G
    J Clin Virol; 2014 Dec; 61(4):540-7. PubMed ID: 25453331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the PapilloCheck® assay with the digene HC2 HPV DNA assay for the detection of 13 high-risk human papillomaviruses in cervical and anal scrapes.
    Didelot MN; Boulle N; Damay A; Costes V; Segondy M
    J Med Virol; 2011 Aug; 83(8):1377-82. PubMed ID: 21678441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human Papillomavirus negative but dyskaryotic cervical cytology: re-analysis of molecular testing.
    Peevor R; Bowden S; Jones J; Fiander AN; Hibbitts S
    J Clin Virol; 2009 Apr; 44(4):322-4. PubMed ID: 19264544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.